Biomarkers for differentiating grade II meningiomas from grade I: a systematic review

References

• Gupta S, Mukherjee S, Syed P, et al. Evaluation of autoantibody signatures in meningioma patients using human proteome arrays. Oncotarget 2017;8:58443–56.
   PubMedGoogle Scholar
• Norden AD, Drappatz J, Wen PY. Targeted drug therapy for meningiomas. Neurosurg Focus 2007;23:E12.
   PubMedGoogle Scholar
• Laukamp KR, Shakirin G, Baeßler B, et al. Accuracy of radiomics-based feature analysis on multiparametric magnetic resonance images for noninvasive meningioma grading. World Neurosurg 2019;132:e366–90.
   PubMed Web of Science ®Google Scholar
• Magill ST, Vasudevan HN, Seo K, et al. Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. Nat Commun 2020;11:4803.
   PubMed Web of Science ®Google Scholar
• Erkan EP, Ströbel T, Dorfer C, et al. Circulating tumor biomarkers in meningiomas reveal a signature of equilibrium between tumor growth and immune modulation. Front Oncol 2019;9:1031.
   PubMed Web of Science ®Google Scholar
• Goldbrunner R, Minniti G, Preusser M, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 2016;17:e383–91.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803–20.
   PubMed Web of Science ®Google Scholar
• Backer-Grøndahl T, Moen BH, Torp SH. The histopathological spectrum of human meningiomas. Int J Clin Exp Path 2012;5:231–42.
   PubMed Web of Science ®Google Scholar
• Harmancı AS, Youngblood MW, Clark VE, et al. Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nat Commun 2017;8:14433.
   PubMed Web of Science ®Google Scholar
• Ülgen E, Bektaşoğlu PK, Sav MA, et al. Meningiomas display a specific immunoexpression pattern in a rostrocaudal gradient: an analysis of 366 patients. World Neurosurg 2019;123:e520–35.
   PubMed Web of Science ®Google Scholar
• Harter PN, Braun Y, Plate KH. Classification of meningiomas-advances and controversies. Chin Clin Oncol 2017;6:S2.
   PubMed Web of Science ®Google Scholar
• Rogers CL, Perry A, Pugh S, et al. Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro Oncol 2016;18:565–74.
   PubMed Web of Science ®Google Scholar
• Katz LM, Hielscher T, Liechty B, et al. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol 2018;135:955–63.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Jia GJ, Zhang GB, et al. A logistic regression model for detecting the presence of malignant progression in atypical meningiomas. World Neurosurg 2019;126:e392–e401.
   PubMed Web of Science ®Google Scholar
• Parada CA, Osbun JW, Busald T, et al. Phosphoproteomic and kinomic signature of clinically aggressive grade I (1.5) meningiomas reveals RB1 signaling as a novel mediator and biomarker. Clin Cancer Res 2020;26:193–205.
   PubMed Web of Science ®Google Scholar
• Hirato J, Nakazato Y, Hirato M, Histological grading of meningioma based on MIB-1 immunoreactivity. In: Nagai M, ed. Tokyo: Brain Tumor; 1996:69–78.
   Google Scholar
• Liu N, Song SY, Jiang JB, Wang TJ, Yan CX. The prognostic role of Ki-67/MIB-1 in meningioma: a systematic review with meta-analysis. Medicine 2020;99:e18644.
   PubMed Web of Science ®Google Scholar
• Haddad AF, et al. WHO Grade I meningioma recurrence: identifying high risk patients using histopathological features and the MIB-1 index. Front Oncol 2020;10:1522.
   PubMed Web of Science ®Google Scholar
• Li J, Liang R, Song C, Xiang Y, Liu Y. Prognostic value of Ki-67/MIB-1 expression in meningioma patients: a meta-analysis. Crit Rev Eukaryot Gene Expr 2019;29:141–150.
   PubMed Web of Science ®Google Scholar
• Tyagi A, Chakrabarty A, Franks A. MIB1 proliferation index in meningiomas: does it predict recurrence? A clinicopathological study. Br J of Neurosurg 2004;18:357–61.
   PubMed Web of Science ®Google Scholar
• Sahm F, Schrimpf D, Stichel D, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 2017;18:682–94.
   PubMed Web of Science ®Google Scholar
• Suppiah S, Nassiri F, Bi WL, et al. 'Molecular and translational advances in meningiomas'. Neuro-Oncology 2019;21:i4–i17.
   PubMed Web of Science ®Google Scholar
• Jenkinson MD, Santarius T, Zadeh G, Aldape KD. Atypical meningioma—is it time to standardize surgical sampling techniques? Neuro-oncology 2016;19:453–54.
   Web of Science ®Google Scholar
• Sherratt FC, Brown SL, Haylock BJ, et al. Challenges conveying clinical equipoise and exploring patient treatment preferences in an oncology trial comparing active monitoring with radiotherapy (ROAM/EORTC 1308). Oncologist 2020;25:e691–e700.
   PubMed Web of Science ®Google Scholar
• Barresi V, Lionti S, Caliri S, Caffo M. Histopathological features to define atypical meningioma: What does really matter for prognosis? Brain Tumor Pathol 2018;35:168–80.
   PubMed Web of Science ®Google Scholar
• Barrett OC, Hackney JR, McDonald AM, et al. Pathologic predictors of local recurrence in atypical meningiomas following gross total resection. Int J Radiat Oncol Biol Phys 2019;103:453–9.
   PubMedGoogle Scholar
• Budohoski KP, Clerkin J, Millward CP, et al. Predictors of early progression of surgically treated atypical meningiomas. Acta Neurochir (Wien) 2018;160:1813–22.
   PubMed Web of Science ®Google Scholar
• Endo T, Narisawa A, Ali HSM, et al. A study of prognostic factors in 45 cases of atypical meningioma. Acta Neurochir (Wien) 2016;158:1661–67.
   PubMed Web of Science ®Google Scholar
• Hardesty DA, Wolf AB, Brachman DG, et al. The impact of adjuvant stereotactic radiosurgery on atypical meningioma recurrence following aggressive microsurgical resection. J Neurosurg 2013;119:475–81.
   PubMed Web of Science ®Google Scholar
• Kim D, Niemierko A, Hwang WL, et al. Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas. J Neurosurg 2018;128:1123–32.
   PubMed Web of Science ®Google Scholar
• Nowak A, Dziedzic T, Krych P, Czernicki T, Kunert P, Marchel A. Benign versus atypical meningiomas: risk factors predicting recurrence. Neurol Neurochir Pol 2015;49:1–10.
   PubMed Web of Science ®Google Scholar
• Sun SQ, Kim AH, Cai C, et al. Management of atypical cranial meningiomas, part 1: predictors of recurrence and the role of adjuvant radiation after gross total resection. Neurosurgery 2014b;75:347–354. discussion 354-345; quiz 355.
   PubMed Web of Science ®Google Scholar
• Vranic A, Popovic M, Cör A, Prestor B, Pizem J. Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: a study of 86 patients. Neurosurgery 2010;67:1124–32.
   PubMed Web of Science ®Google Scholar
• Magill ST, Young JS, Chae R, et al. Relationship between tumor location, size, and WHO grade in meningioma. Neurosurg Focus 2018;44:E4.
   PubMed Web of Science ®Google Scholar
• Fleming CW, Parsai S, Suh JH. A management dilemma: adjuvant radiotherapy after gross total resection of atypical meningioma. Translational Cancer Research 2018;8:1–3.
   Web of Science ®Google Scholar
• Jenkinson MD, Javadpour M, Haylock BJ, et al. The ROAM/EORTC-1308 trial: radiation versus observation following surgical resection of atypical meningioma: study protocol for a randomised controlled trial. Trials 2015;16:19.
   PubMed Web of Science ®Google Scholar
• NRG-BN003. 2018. Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery, 2018. [online]. Clinical Trials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03180268 [Accessed 17/01/2021 2021].
   Google Scholar
• Rogers CL, Won M, Vogelbaum MA, et al. High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. Int J Radiat Oncol Biol Phys 2020;106:790–9.
   PubMed Web of Science ®Google Scholar
• Rogers L, Zhang P, Vogelbaum MA, et al. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg 2018;129:35–47.
   PubMed Web of Science ®Google Scholar
• Sun SQ, Cai C, Murphy RKJ, et al. Management of atypical cranial meningiomas, part 2: predictors of progression and the role of adjuvant radiation after subtotal resection. Neurosurgery 2014a;75:356–63. discussion 363.
   PubMed Web of Science ®Google Scholar
• Abbritti RV, Polito F, Cucinotta M, et al. Meningiomas and proteomics: focus on new potential biomarkers and molecular pathways. Cancer Genomics Proteomics 2016;13:369–79.
   PubMed Web of Science ®Google Scholar
• Brastianos PK, Horowitz PM, Santagata S, et al. 'Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations'. Nat Genet 2013;45:285–9.
   PubMed Web of Science ®Google Scholar
• Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013;339:1077–80.
   PubMed Web of Science ®Google Scholar
• Clark VE, Harmancı AS, Bai H, et al. 'Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas'. Nat Genet 2016;48:1253–59.
   PubMed Web of Science ®Google Scholar
• Nigim F, Wakimoto H, Kasper EM, Ackermans L, Temel Y. Emerging Medical Treatments for Meningioma in the Molecular Era'. Biomedicines 2018;6:86.
   Web of Science ®Google Scholar
• Nowosielski M, Galldiks N, Iglseder S, et al. Diagnostic challenges in meningioma. Neuro-oncology 2017;19:1588–98.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097-e1000097.
   Web of Science ®Google Scholar
• Osunronbi T, Sofela A, Sharma H, Muquit S. Traumatic pneumorrhachis: systematic review and an illustrative case. Neurosurg Rev 2020;44(2):731–39.
   PubMed Web of Science ®Google Scholar
• Adeli A, Hess K, Mawrin C, et al. Prediction of brain invasion in patients with meningiomas using preoperative magnetic resonance imaging. Oncotarget 2018;9:35974–82.
   PubMedGoogle Scholar
• Park YW, Oh J, You SC, et al. Radiomics and machine learning may accurately predict the grade and histological subtype in meningiomas using conventional and diffusion tensor imaging. Eur Radiol 2019;29:4068–76.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Man C, Gong L, et al. A deep learning radiomics model for preoperative grading in meningioma. Eur J Radiol 2019;116:128–34.
   PubMed Web of Science ®Google Scholar
• Yiping L, Kawai S, Jianbo W, Li L, Daoying G, Bo Y. Evaluation parameters between intra-voxel incoherent motion and diffusion-weighted imaging in grading and differentiating histological subtypes of meningioma: A prospective pilot study. J Neurol Sci 2017;372:60–9.
   PubMed Web of Science ®Google Scholar
• Lu Y, Xiong J, Yina B, et al. The role of three-dimensional pseudo-continuous arterial spin labelling in grading and differentiating histological subgroups of meningiomas. Clin Radiol 2018;73:176–84.
   PubMed Web of Science ®Google Scholar
• Spille DC, Sporns PB, Heß K, Stummer W, Brokinkel B. Prediction of high-grade histology and recurrence in meningiomas using routine preoperative magnetic resonance imaging: a systematic review. World Neurosurg 2019;128:174–81.
   PubMed Web of Science ®Google Scholar
• Hale AT, Stonko, Wang L, Strother MK, Chambless LB . Machine learning analyses can differentiate meningioma grade by features on magnetic resonance imaging. Neurosurg Focus 2018;45:E4.
   PubMed Web of Science ®Google Scholar
• Soon WC, Fountain DM, Koczyk K, et al. Correlation of volumetric growth and histological grade in 50 meningiomas. Acta Neurochir (Wien 2017;159:2169–77.
   PubMed Web of Science ®Google Scholar
• Balmaceda C, Critchell D, Mao X, et al. Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy. J Neurooncol 2006;76:185–91.
   PubMed Web of Science ®Google Scholar
• Chiang GC, Kovanlikaya I, Choi C, et al. Magnetic resonance spectroscopy, positron emission tomography and radiogenomics-relevance to glioma. Front Neurol 2018;9:33.
   PubMed Web of Science ®Google Scholar
• Lin MC, Li CZ, Hsieh CC, et al. Preoperative grading of intracranial meningioma by magnetic resonance spectroscopy (1H-MRS). PLoS One 2018;13:e0207612.
   PubMed Web of Science ®Google Scholar
• Joo B, Han K, Choi YS, et al. Amide proton transfer imaging for differentiation of benign and atypical meningiomas. Eur Radiol 2018;28:331–9.
   PubMed Web of Science ®Google Scholar
• Mitamura K, Yamamoto Y, Norikane T, et al. Correlation of (18)F-FDG and (11)C-methionine uptake on PET/CT with Ki-67 immunohistochemistry in newly diagnosed intracranial meningiomas. Ann Nucl Med 2018;32:627–33.
   PubMed Web of Science ®Google Scholar
• Tomura N, Saginoya T, Goto H. 11C-methionine positron emission tomography/computed tomography versus 18F-fluorodeoxyglucose positron emission tomography/computed tomography in evaluation of residual or recurrent world health organization grades II and III meningioma after treatment. J Comput Assist Tomogr 2018;42:517–21.
   PubMed Web of Science ®Google Scholar
• Abtahi S, Hakimrabet S, Malekzadeh M, Deghanian AR, Ghaderi A . Investigating the levels of soluble extracellular domain of HER2 protein in the sera of meningioma patients. Turk Neurosurg 2019;29:9–13.
   PubMed Web of Science ®Google Scholar
• Mashayekhi F, Saberi A, Mashayekhi S. Serum TIMP1 and TIMP2 concentration in patients with different grades of meningioma. Clin Neurol Neurosurg 2018;170:84–7.
   PubMed Web of Science ®Google Scholar
• Sofela AA, Hilton DA, Ammoun S, et al. Fibulin-2: a novel biomarker for differentiating grade II from grade I meningiomas. Int J Mol Sci 2021;22(2):560.
   Web of Science ®Google Scholar
• Barski D, Wolter M, Reifenberger G, Riemenschneider MJ. Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol 2010;20:623–31.
   PubMed Web of Science ®Google Scholar
• Rooprai HK, Martin AJ, King A, et al. Comparative gene expression profiling of ADAMs, MMPs, TIMPs, EMMPRIN, EGF-R and VEGFA in low grade meningioma. Int J Oncol 2016;49:2309–18.
   PubMed Web of Science ®Google Scholar
• Potti A, Panwalkar A, Langness E, et al. Role of her-2/neu overexpression and clinical features at presentation as predictive factors in meningiomas. Am J Clin Oncol 2004;27:452–6.
   PubMed Web of Science ®Google Scholar
• Parada CA, Osbun J, Kaur S, et al. Kinome and phosphoproteome of high-grade meningiomas reveal AKAP12 as a central regulator of aggressiveness and its possible role in progression. Sci Rep 2018;8:2098.
   PubMed Web of Science ®Google Scholar
• Tauziede-Espariat A, Parfait B, Besnard A, et al. Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: a comprehensive immunophenotypical and molecular analysis. Brain Pathol 2018;28:466–74.
   PubMed Web of Science ®Google Scholar
• Tsai WC, Hueng DY, Nieh S, Gao HW. ARID4B is a good biomarker to predict tumour behaviour and decide WHO grades in gliomas and meningiomas. J Clin Pathol 2017;70:162–7.
   PubMed Web of Science ®Google Scholar
• Shen L, Lin D, Cheng L, et al. Is DNA methylation a ray of sunshine in predicting meningioma prognosis? Front Oncol 2020;10:1323.
   PubMed Web of Science ®Google Scholar
• Cagney DN, Sul J, Huang RY, et al. The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. Neuro Oncol 2018;20:1162–72.
   PubMed Web of Science ®Google Scholar
• Azizyan A, Eboli P, Drazin D, Mirocha J, Maya MM, Bannykh S. Differentiation of benign angiomatous and microcystic meningiomas with extensive peritumoral edema from high grade meningiomas with aid of diffusion weighted MRI. BioMed Res Int 2014;2014:650939.
   PubMed Web of Science ®Google Scholar
• Czyz M, Radwan H, Li JY, Filippi CG, Tykocki T, Schulder M. Fractal analysis may improve the preoperative identification of atypical meningiomas. Neurosurgery 2016;80:300–8.
   Web of Science ®Google Scholar
• Hamerla G, Meyer HJ, Schob S, et al. Comparison of machine learning classifiers for differentiation of grade 1 from higher gradings in meningioma: A multicenter radiomics study. Magn Reson Imaging 2019;63:244–9.
   PubMed Web of Science ®Google Scholar
• Hsu CC, Pai CY, Kao HW, et al. Do aggressive imaging features correlate with advanced histopathological grade in meningiomas? Journal of Clinical Neuroscience 2010;17:584–7.
   PubMed Web of Science ®Google Scholar
• Macarthur KM, Kao GD, Chandrasekaran S, et al. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res 2014;74:2152–59.
   PubMed Web of Science ®Google Scholar
• Negroni C, Hilton DA, Ercolano E, et al. GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma. EBioMedicine 2020;59:102941.
   PubMed Web of Science ®Google Scholar
• Akers JC, Ramakrishnan V, Kim R, et al. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS One 2013;8:e78115.
   PubMed Web of Science ®Google Scholar
• Jia L, Liu C, Xin Y, et al. Evaluating EFEMP1 in cerebrospinal fluid and serum as a potential diagnosis biomarker for meningiomas. Clin Lab 2017;63:1717–22.
   PubMed Web of Science ®Google Scholar
• Champeaux C, Houston D, Dunn L, Resche-Rigon M. Intracranial WHO grade I meningioma: a competing risk analysis of progression and disease-specific survival. Acta Neurochir (Wien) 2019. Epub ahead of print. doi: https://doi.org/10.1007/s00701-019-04096-9.
   Web of Science ®Google Scholar
• Corniola MV, Lemée J-M, Meling TR. Histological transformation in recurrent WHO grade I meningiomas. Sci Rep 2020;10:11220.
   PubMed Web of Science ®Google Scholar
• Marciscano AE, Stemmer-Rachamimov AO, Niemierko A, et al. Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. J Neurosurg 2016;124:106.
   PubMed Web of Science ®Google Scholar